Arcus Biosciences (RCUS) EBT Margin (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly EBT Margin of 752.94% for Q1 2026, down 35294.0% year-over-year from N/an in Q1 2025, and down 134.41% quarter-over-quarter from 321.21% in Q4 2025.
Powered by 
Analysis
Arcus Biosciences (RCUS) EBT Margin (2017 - 2026) Analysis & Trends
Arcus Biosciences' EBT Margin history runs 10 years deep, the most recent figure standing at 752.94% for Q1 2026.
- In Q1 2026, EBT Margin fell 35294.0% year-over-year to 752.94%; the TTM figure through Mar 2026 stood at 156.36% (up 12024.0% YoY), while the FY2025 annual figure was 142.91%, down 3361.0% from the prior year.
- EBT Margin for Q1 2026 stood at 752.94%, down from 321.21% in the prior quarter.
- The five-year high for EBT Margin was 2.76% in Q1 2024, with the low at 752.94% in Q1 2026.
- The 5-year median for EBT Margin is 283.59% (2023), against an average of 322.04%.
- The sharpest annual moves came in 2022 and 2025: EBT Margin surged 62720 bps in 2022, then slumped 39724 bps in 2025.
- Arcus Biosciences' EBT Margin stood at 197.06% in 2022, then sank by 190 bps to 571.43% in 2023, then soared by 37 bps to 357.69% in 2024, then advanced by 10 bps to 321.21% in 2025, then plunged by 134 bps to 752.94% in 2026.
- Business Quant data shows RCUS's EBT Margin at 752.94% in Q1 2026, 321.21% in Q4 2025, and 519.23% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 12.09% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -2.67% |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | -221.95% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -221.95% |
| Mar 31, 2026 | -752.94% |
| Dec 31, 2025 | -321.21% |
| Sep 30, 2025 | -519.23% |
| Mar 31, 2025 | -400.00% |
| Dec 31, 2024 | -357.69% |
| Sep 30, 2024 | -191.67% |
| Jun 30, 2024 | -238.46% |
| Mar 31, 2024 | -2.76% |
| Dec 31, 2023 | -571.43% |
| Sep 30, 2023 | -215.63% |
| Jun 30, 2023 | -255.17% |
| Mar 31, 2023 | -312.00% |
| Dec 31, 2022 | -197.06% |
| Sep 30, 2022 | -196.97% |
| Jun 30, 2022 | -248.15% |
| Mar 31, 2022 | -372.22% |
| Dec 31, 2021 | 79.39% |
| Sep 30, 2021 | -824.17% |
| Jun 30, 2021 | -802.98% |